^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INCA32459

    i
    Other names: INCA32459, INCA32459-101, INCA 32459, INCA32459101, INCA3-2459, INCA32459 101
    Associations

    News

    Trials
    Company:
    Incyte, Merus
    Drug class:
    PD1 inhibitor, LAG-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting | N=120 --> 46
    Enrollment closed • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    INCA32459
    2years
    Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies (clinicaltrials.gov)
    P1, N=120, Recruiting, Incyte Corporation | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    INCA32459
    2years
    Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Incyte Corporation
    New P1 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    INCA32459
    2years
    A human bispecific antibody targeting LAG-3 and PD-1 (INCA32459) potently activates exhausted T cells (SITC 2022)
    In a human MDA-MB-231 breast tumor model in CD34 + humanized NSG mice, INCA32459 treatment decreased tumor growth compared with a combination of PD-1 (pembrolizumab) and LAG-3 (relatlimab analog) antibodies. Conclusions We have developed INCA32459, a potent dual inhibitor of PD-1 and LAG-3 in preclinical models, which induces activation of exhausted T cells to a greater extent than a combination of bivalent monospecific antibodies targeting PD-1 (nivolumab analog) and LAG-3 (relatlimab analog). These data support the clinical evaluation of INCA32459, and a phase 1 study in cancer patients is underway.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3) • CD34 (CD34 molecule) • IL2 (Interleukin 2)
    |
    LAG3 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • relatlimab (BMS-986016) • INCA32459